Back to News
Market Impact: 0.25
Lilly's Taltz Plus Zepbound Shows Durable One-Year Benefits In Psoriatic Disease And Obesity
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
Eli Lilly reported Phase 3b one-year data showing that combining Taltz (ixekizumab) with Zepbound (tirzepatide) improved and sustained outcomes in adults with psoriatic disease and obesity. While specific efficacy metrics weren’t provided in the excerpt, the update is a positive clinical signal that could support commercial momentum for both franchises.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
LLY0.55
More News
- Here's our monthly update on our 32 stocks, including 2 more names to buy
- Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- Penske Automotive agrees to be taken private by Penske, Mitsui
- Faraday Copper completes acquisition of BHP’s San Manuel project
- Supermicro promised a new CFO in December 2024. A $2.5 billion smuggling case and a co-founder’s arrest later, it has one